Core Viewpoint - Stryker Corporation is expected to report its first-quarter 2025 results on May 1, with earnings estimated at $2.73 per share, reflecting a year-over-year increase of 9.2% and revenues projected at $5.70 billion, indicating an 8.8% growth from the previous year [1][2]. Group 1: Performance Drivers - The anticipated strong performance in the first quarter is attributed to robust sales in the U.S. market across various segments, including Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako [3]. - The MedSurg and Neurotechnology segment experienced significant sales growth in the previous quarter, driven by the Surgical Technologies and orthopedic implants businesses, which is expected to continue [4]. - Recent product launches, including the next generation of SurgiCount+ and the Oculan Lighting Platform, are likely to contribute to additional sales in the first quarter [5]. Group 2: Product Portfolio and Acquisitions - The commercialization of the Pangea Plating system and strong sales of the LIFEPAK 35 defibrillator are expected to have positively impacted first-quarter results [6]. - New products like the Osteotomy Truss System and Ankle Truss System are anticipated to enhance the Foot & Ankle portfolio, improving surgical precision and patient outcomes [7]. - Stryker has completed five acquisitions in the latter half of 2024, which are expected to be accretive to quarterly results, enhancing its product offerings in various medical fields [8]. Group 3: Sales Estimates - Sales estimates for the MedSurg and Neurotechnology segments are projected at $3.75 billion, while Orthopaedics & Spine segments are estimated at $2.57 billion. U.S. sales are expected to be $4.74 billion, with international sales at $1.59 billion [9]. Group 4: Market Challenges - Ongoing challenges in China due to volume-based procurement policies and rising tariffs may partially offset international growth, although Stryker is addressing inflationary pressures and has recognized improved pricing and reduced cost pressures [10].

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates ...

Contacts For investor inquiries: Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Inves ...

The current level reflects a downward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. In its upcoming report, Stryker (SYK) is predicted by Wall Street analysts to post quarterly earnings of $2.73 per share, reflecting an increase of 9.2% compared to the same period last year. Revenues are forecasted to be $5.7 billion, representing a year-over ...

Portage, Michigan, April 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2025 on Thursday, May 1, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, May 1, 2025, to discuss its firs ...

VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE:SYK). The business will operate as a standalone company under the nam ...

VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE: SYK). The business will operate as a standalone company under the na ...

Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC. Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve ...

Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Manny brings more than 30 years of experience leading high-performing organizations and advising senior executives on large-scale corporate transformations. He currently serves as Chairman of Bain & Company, following his tenure as Worldwide Managing Partn ...

Core Points - Stryker has scheduled its 2025 Annual Meeting of Shareholders for May 8, 2025, at 9:30 a.m. Eastern Time, to be held virtually [1] - A recording of the annual meeting will be available from May 9, 2025, at 10:30 a.m. Eastern Time until the filing of the definitive proxy statement for the 2026 Annual Meeting [2] - Stryker is a global leader in medical technologies, impacting over 150 million patients annually with innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3] Company Information - Stryker offers a range of medical technologies aimed at improving healthcare outcomes [3] - The company provides contact information for investor and media inquiries, indicating a structured approach to communication [4]